Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for the Treatment of Primary Sjögren’s Syndrome
ChiCTR2500108666Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ivarmacitinib in primary Sjögren's syndrome (2 cohorts), sponsored by Union Hospital. Primary endpoint: Proportion of patients with ESSDAI reduction ≥2 at Week 24. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2500108666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108666.